Explore more publications!

Bangladesh Health Times Press Releases

Labels On
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
Info
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
India Announces Pinnacle Global Autism Framework Based on 19 Million+ Therapy Sessions Success and 97% Measured Outcomes
Human Appeal announces summertime UK Comedy Tour
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
AV Global Overseas Launches New Initiatives to Empower Indian Students for Study Abroad Success
AIDA Country Report on Romania – Update on 2024

AIDA Country Report on Romania – Update on 2024

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
Hang Tag Applicators Market to Hit USD 4.3 Billion by 2035 as Innovators Redefine Smart Labeling Technologies
Lyocell Fiber Market is Expected to Reach USD 6.0 Billion by 2035, Fact.MR Report
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Energy Storage Systems Market Size Set to Hit USD 569.39 Bn by 2034 Driven by Grid Firming and Renewables
Patient Monitoring and Ultrasound Devices Display Market Projected to Exceed USD 10.6 Billion by 2034 | TMR
Fortified Rice Market Valued at USD 18.2 Bn in 2022, Set to Grow at a 5.7% CAGR by 2031 | TMR

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions